Cargando…
A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common malignancy of liver cancer. However, treatment of HCC is still severely limited due to limitation of drug therapy. We aimed to screen more possible target genes and candidate drugs for HCC, exploring the possibility of drug treatments...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946504/ https://www.ncbi.nlm.nih.gov/pubmed/35326724 http://dx.doi.org/10.3390/cancers14061573 |
_version_ | 1784674209198243840 |
---|---|
author | Yuan, Meng Shong, Koeun Li, Xiangyu Ashraf, Sajda Shi, Mengnan Kim, Woonghee Nielsen, Jens Turkez, Hasan Shoaie, Saeed Uhlen, Mathias Zhang, Cheng Mardinoglu, Adil |
author_facet | Yuan, Meng Shong, Koeun Li, Xiangyu Ashraf, Sajda Shi, Mengnan Kim, Woonghee Nielsen, Jens Turkez, Hasan Shoaie, Saeed Uhlen, Mathias Zhang, Cheng Mardinoglu, Adil |
author_sort | Yuan, Meng |
collection | PubMed |
description | SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common malignancy of liver cancer. However, treatment of HCC is still severely limited due to limitation of drug therapy. We aimed to screen more possible target genes and candidate drugs for HCC, exploring the possibility of drug treatments from systems biological perspective. We identified ten candidate target genes, which are hub genes in HCC co-expression networks, which also possess significant prognostic value in two independent HCC cohorts. The rationality of these target genes was well demonstrated through variety analyses of patient expression profiles. We then screened candidate drugs for target genes and finally identified withaferin-a and mitoxantrone as the candidate drug for HCC treatment. The drug effectiveness was validated in in vitro model and computational analysis, providing more evidence for our drug repositioning method and results. ABSTRACT: Hepatocellular carcinoma (HCC) is a malignant liver cancer that continues to increase deaths worldwide owing to limited therapies and treatments. Computational drug repurposing is a promising strategy to discover potential indications of existing drugs. In this study, we present a systematic drug repositioning method based on comprehensive integration of molecular signatures in liver cancer tissue and cell lines. First, we identify robust prognostic genes and two gene co-expression modules enriched in unfavorable prognostic genes based on two independent HCC cohorts, which showed great consistency in functional and network topology. Then, we screen 10 genes as potential target genes for HCC on the bias of network topology analysis in these two modules. Further, we perform a drug repositioning method by integrating the shRNA and drug perturbation of liver cancer cell lines and identifying potential drugs for every target gene. Finally, we evaluate the effects of the candidate drugs through an in vitro model and observe that two identified drugs inhibited the protein levels of their corresponding target genes and cell migration, also showing great binding affinity in protein docking analysis. Our study demonstrates the usefulness and efficiency of network-based drug repositioning approach to discover potential drugs for cancer treatment and precision medicine approach. |
format | Online Article Text |
id | pubmed-8946504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89465042022-03-25 A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma Yuan, Meng Shong, Koeun Li, Xiangyu Ashraf, Sajda Shi, Mengnan Kim, Woonghee Nielsen, Jens Turkez, Hasan Shoaie, Saeed Uhlen, Mathias Zhang, Cheng Mardinoglu, Adil Cancers (Basel) Article SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common malignancy of liver cancer. However, treatment of HCC is still severely limited due to limitation of drug therapy. We aimed to screen more possible target genes and candidate drugs for HCC, exploring the possibility of drug treatments from systems biological perspective. We identified ten candidate target genes, which are hub genes in HCC co-expression networks, which also possess significant prognostic value in two independent HCC cohorts. The rationality of these target genes was well demonstrated through variety analyses of patient expression profiles. We then screened candidate drugs for target genes and finally identified withaferin-a and mitoxantrone as the candidate drug for HCC treatment. The drug effectiveness was validated in in vitro model and computational analysis, providing more evidence for our drug repositioning method and results. ABSTRACT: Hepatocellular carcinoma (HCC) is a malignant liver cancer that continues to increase deaths worldwide owing to limited therapies and treatments. Computational drug repurposing is a promising strategy to discover potential indications of existing drugs. In this study, we present a systematic drug repositioning method based on comprehensive integration of molecular signatures in liver cancer tissue and cell lines. First, we identify robust prognostic genes and two gene co-expression modules enriched in unfavorable prognostic genes based on two independent HCC cohorts, which showed great consistency in functional and network topology. Then, we screen 10 genes as potential target genes for HCC on the bias of network topology analysis in these two modules. Further, we perform a drug repositioning method by integrating the shRNA and drug perturbation of liver cancer cell lines and identifying potential drugs for every target gene. Finally, we evaluate the effects of the candidate drugs through an in vitro model and observe that two identified drugs inhibited the protein levels of their corresponding target genes and cell migration, also showing great binding affinity in protein docking analysis. Our study demonstrates the usefulness and efficiency of network-based drug repositioning approach to discover potential drugs for cancer treatment and precision medicine approach. MDPI 2022-03-19 /pmc/articles/PMC8946504/ /pubmed/35326724 http://dx.doi.org/10.3390/cancers14061573 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yuan, Meng Shong, Koeun Li, Xiangyu Ashraf, Sajda Shi, Mengnan Kim, Woonghee Nielsen, Jens Turkez, Hasan Shoaie, Saeed Uhlen, Mathias Zhang, Cheng Mardinoglu, Adil A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma |
title | A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma |
title_full | A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma |
title_fullStr | A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma |
title_full_unstemmed | A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma |
title_short | A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma |
title_sort | gene co-expression network-based drug repositioning approach identifies candidates for treatment of hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946504/ https://www.ncbi.nlm.nih.gov/pubmed/35326724 http://dx.doi.org/10.3390/cancers14061573 |
work_keys_str_mv | AT yuanmeng agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT shongkoeun agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT lixiangyu agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT ashrafsajda agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT shimengnan agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT kimwoonghee agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT nielsenjens agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT turkezhasan agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT shoaiesaeed agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT uhlenmathias agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT zhangcheng agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT mardinogluadil agenecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT yuanmeng genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT shongkoeun genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT lixiangyu genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT ashrafsajda genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT shimengnan genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT kimwoonghee genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT nielsenjens genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT turkezhasan genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT shoaiesaeed genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT uhlenmathias genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT zhangcheng genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma AT mardinogluadil genecoexpressionnetworkbaseddrugrepositioningapproachidentifiescandidatesfortreatmentofhepatocellularcarcinoma |